Bristol-myers Squibb Pharma Company

Wyeth

Albany Molecular Research, Inc.

Siena Biotech S.p.a.

Simon Nicolas Haydar

Albert Jean Robichaud

Taekyu Lee

Ian S Mitchell

Wenting Chen

Wei Deng

David M Zawrotny

Michael G Yang

Christopher D McClung

Patrick Michael Andrae

Emilie J Calvello

Emilie J B Calvello

Christopher D Mc Clung

Emile J B Calvello

Parthasarathl Rajagopalan

Boyd Lynn Harrison

Heedong Yun

Maurizio Varrone

Arianna Nencini

Chiara Ghiron

Iolanda Micco

Riccardo Zanaletti

Laura Maccari

Hendrick Bothmann

Carmela Pratelli

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system. 

Modulators of &#x3b1;7 nicotinic acetylcholine receptors and therapeutic uses thereof

The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 

Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

The present invention is directed to certain novel compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Substituted heterocycle fused gamma-carbolines

The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Substituted heterocycle fused &#x3b3;-carbolines

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

The present invention relates to a group of aza-anthrapyrazole compounds having antitumor activity, and processes for their preparation. Compositions containing the aza-anthrapyrazole compounds and methods of treating tumors and cancer in mammals with the compounds of the present invention are also disclosed.

Aza-benzothiopyranoindazoles with antitumor activity

Growing community of inventors

Newtown, PA, United States of America

Simon Nicolas Haydar